Phaos Technology Holdings (Cayman) (POAS) Receivables (2024 - 2025)

Phaos Technology Holdings (Cayman) (POAS) posted Receivables of $47623.0 for Q4 2025, down 97.9% on a QoQ basis from $2.3 million in Q2 2025.

Phaos Technology Holdings (Cayman) (POAS) Receivables (2024 - 2025) Analysis & Trends

Phaos Technology Holdings (Cayman)'s Receivables history runs 2 years deep, the most recent figure standing at $47623.0 for Q4 2025.

Quarterly Receivables changed N/A year-over-year to $47623.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was $47623.0 (changed N/A YoY) and the FY2025 annual result came in at $2.3 million, up 161.74% from the prior year.
Receivables was $47623.0 for Q4 2025 at Phaos Technology Holdings (Cayman), down from $2.3 million in the prior quarter.
Across five years, Receivables topped out at $2.3 million in Q2 2025 and bottomed at $47623.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Abbott Laboratories	183.06 Bn	175.76 Bn	6.27 Bn	8.21 Bn
2	Stryker	128.66 Bn	125.78 Bn	3.81 Bn	3.57 Bn
3	Medtronic	108.82 Bn	99.60 Bn	6.41 Bn	6.64 Bn
4	Boston Scientific	68.43 Bn	66.98 Bn	3.61 Bn	3.03 Bn
5	Edwards Lifesciences	48.29 Bn	44.61 Bn	1.29 Bn	973.00 Mn
6	GE HealthCare Technologies	28.37 Bn	26.08 Bn	1.98 Bn	4.50 Bn
7	Dexcom	28.29 Bn	27.18 Bn	750.30 Mn	1.11 Bn
8	Smith & Nephew	26.89 Bn	26.31 Bn	-	1.55 Bn
9	Koninklijke Philips	25.43 Bn	22.31 Bn	2.07 Bn	3.80 Bn
10	Phaos Technology Holdings (Cayman)	6.17 Mn	6.12 Mn	-	47,623.00

Download Data